Santen Pharmaceutical Co Ltd
TSE:4536
Santen Pharmaceutical Co Ltd
TSE:4536
Price:
1 670.5
JPY
0.39%
Market Closed
Market Cap:
606.7B
JPY
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Santen Pharmaceutical Co Ltd
1670.5
+6.5 (+0.39%)
| 52 Week Range |
1 334
1 876.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Santen Pharmaceutical Co Ltd
Balance Sheet
Balance Sheet Decomposition
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co Ltd
| Current Assets | 233.9B |
| Cash & Short-Term Investments | 90.2B |
| Receivables | 83.6B |
| Other Current Assets | 60B |
| Non-Current Assets | 200.3B |
| Long-Term Investments | 24.6B |
| PP&E | 72.2B |
| Intangibles | 83.2B |
| Other Non-Current Assets | 20.2B |
| Current Liabilities | 89.9B |
| Accounts Payable | 45.6B |
| Other Current Liabilities | 44.3B |
| Non-Current Liabilities | 37.6B |
| Long-Term Debt | 32.6B |
| Other Non-Current Liabilities | 4.9B |
Balance Sheet
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co Ltd
Currency: JPY
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
65 945
|
99 818
|
53 297
|
69 283
|
70 796
|
91 430
|
62 888
|
83 014
|
57 903
|
94 582
|
|
| Cash Equivalents |
65 945
|
99 818
|
53 297
|
69 283
|
70 796
|
91 430
|
62 888
|
83 014
|
57 903
|
94 582
|
|
| Short-Term Investments |
187
|
234
|
333
|
472
|
267
|
452
|
527
|
1 293
|
774
|
379
|
|
| Total Receivables |
61 701
|
65 998
|
70 970
|
78 654
|
84 618
|
86 999
|
95 992
|
99 591
|
107 225
|
90 539
|
|
| Accounts Receivables |
59 607
|
63 950
|
68 799
|
76 115
|
81 957
|
84 224
|
93 028
|
95 992
|
103 608
|
86 953
|
|
| Other Receivables |
2 094
|
2 048
|
2 171
|
2 539
|
2 661
|
2 775
|
2 964
|
3 599
|
3 617
|
3 586
|
|
| Inventory |
20 133
|
24 996
|
28 502
|
30 636
|
35 235
|
35 282
|
41 575
|
37 141
|
39 352
|
43 185
|
|
| Other Current Assets |
2 706
|
3 693
|
3 909
|
4 322
|
3 826
|
4 393
|
5 249
|
8 387
|
8 072
|
7 454
|
|
| Total Current Assets |
150 672
|
194 739
|
157 011
|
183 367
|
194 742
|
218 556
|
206 231
|
229 426
|
213 326
|
236 139
|
|
| PP&E Net |
29 104
|
27 991
|
28 550
|
29 706
|
31 699
|
35 601
|
39 489
|
56 287
|
66 173
|
71 576
|
|
| PP&E Gross |
29 104
|
27 991
|
28 550
|
29 706
|
31 699
|
35 601
|
39 489
|
56 287
|
66 173
|
71 576
|
|
| Accumulated Depreciation |
0
|
55 704
|
57 059
|
60 025
|
53 706
|
56 212
|
60 938
|
64 530
|
68 613
|
72 277
|
|
| Intangible Assets |
77 855
|
77 241
|
116 165
|
112 200
|
108 397
|
97 723
|
103 104
|
116 502
|
88 924
|
75 516
|
|
| Goodwill |
0
|
6 440
|
22 770
|
22 295
|
22 713
|
22 127
|
12 704
|
13 715
|
7 385
|
8 303
|
|
| Long-Term Investments |
34 725
|
44 535
|
29 889
|
35 775
|
30 044
|
30 848
|
37 065
|
36 238
|
37 359
|
24 406
|
|
| Other Long-Term Assets |
5 266
|
4 453
|
4 521
|
5 120
|
3 591
|
3 913
|
6 692
|
7 808
|
8 012
|
19 759
|
|
| Other Assets |
0
|
6 440
|
22 770
|
22 295
|
22 713
|
22 127
|
12 704
|
13 715
|
7 385
|
8 303
|
|
| Total Assets |
304 200
N/A
|
355 399
+17%
|
358 906
+1%
|
388 463
+8%
|
391 186
+1%
|
408 768
+4%
|
405 285
-1%
|
459 976
+13%
|
421 179
-8%
|
435 699
+3%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
14 330
|
17 225
|
17 883
|
22 471
|
29 822
|
22 766
|
24 258
|
24 420
|
25 282
|
24 042
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
9 540
|
9 331
|
4 098
|
500
|
5 726
|
2 912
|
13 965
|
3 056
|
2 748
|
|
| Other Current Liabilities |
30 200
|
46 465
|
26 267
|
35 632
|
30 341
|
39 105
|
51 379
|
57 436
|
61 166
|
66 006
|
|
| Total Current Liabilities |
56 340
|
73 230
|
53 481
|
62 201
|
60 663
|
67 597
|
78 549
|
95 821
|
89 504
|
92 796
|
|
| Long-Term Debt |
25 351
|
12 944
|
7 619
|
3 500
|
3 563
|
6 602
|
7 234
|
18 967
|
33 151
|
31 862
|
|
| Deferred Income Tax |
2 874
|
3 988
|
17 963
|
12 909
|
9 389
|
7 228
|
3 626
|
2 526
|
1 592
|
1 377
|
|
| Minority Interest |
0
|
0
|
819
|
1 734
|
1 672
|
305
|
535
|
645
|
683
|
685
|
|
| Other Liabilities |
7 856
|
5 228
|
23 914
|
22 296
|
24 999
|
24 781
|
6 230
|
5 818
|
3 635
|
4 295
|
|
| Total Liabilities |
92 421
N/A
|
95 390
+3%
|
103 796
+9%
|
102 640
-1%
|
100 286
-2%
|
105 903
+6%
|
95 104
-10%
|
122 487
+29%
|
127 199
+4%
|
129 645
+2%
|
|
| Equity | |||||||||||
| Common Stock |
7 383
|
7 695
|
7 792
|
8 032
|
8 252
|
8 366
|
8 525
|
8 672
|
8 702
|
8 777
|
|
| Retained Earnings |
179 393
|
222 661
|
224 108
|
250 200
|
259 461
|
274 108
|
273 756
|
290 861
|
238 402
|
240 210
|
|
| Additional Paid In Capital |
8 077
|
8 389
|
8 417
|
8 657
|
8 661
|
8 746
|
8 954
|
9 370
|
9 789
|
9 854
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
9 470
|
14 364
|
10 230
|
11 150
|
11 075
|
8 438
|
7 917
|
5 481
|
|
| Treasury Stock |
18
|
0
|
10
|
11
|
1 131
|
1 033
|
934
|
718
|
364
|
1 018
|
|
| Other Equity |
16 944
|
2 612
|
5 333
|
4 581
|
5 427
|
1 528
|
8 805
|
20 866
|
29 534
|
42 750
|
|
| Total Equity |
211 779
N/A
|
260 009
+23%
|
255 110
-2%
|
285 823
+12%
|
290 900
+2%
|
302 865
+4%
|
310 181
+2%
|
337 489
+9%
|
293 980
-13%
|
306 054
+4%
|
|
| Total Liabilities & Equity |
304 200
N/A
|
355 399
+17%
|
358 906
+1%
|
388 463
+8%
|
391 186
+1%
|
408 768
+4%
|
405 285
-1%
|
459 976
+13%
|
421 179
-8%
|
435 699
+3%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
413
|
414
|
406
|
407
|
399
|
399
|
400
|
400
|
376
|
363
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
